Publications by authors named "P A Fehrenbach"
Article Synopsis
- This study explores how regulatory T cells (Tregs) behave in inflammatory bowel diseases like Crohn's disease, focusing on their metabolic processes that impact gut homeostasis.
- Researchers used various advanced techniques (like electron microscopy and mass cytometry) to analyze Tregs' cellular structures and functions in humans and murine models of colitis.
- Key findings show that inhibiting a specific protein (VDAC1) disrupts Treg metabolism and increases sensitivity to inflammation, while manipulating metabolic pathways can restore proper Treg function and potentially inform new therapeutic strategies for inflammatory diseases.
Background & Aims: Incapacitated regulatory T cells (Tregs) contribute to immune-mediated diseases. Inflammatory Tregs are evident during human inflammatory bowel disease (IBD); however, mechanisms driving the development of these cells and their function are not well understood. Therefore, we investigated the role of cellular metabolism in Tregs relevant to gut homeostasis.
View Article and Find Full Text PDFHepatocellular carcinoma (HCC) is a global health burden with increasing incidence, poor prognosis and limited therapeutic options. Natural killer (NK) cells exhibit potent anti-tumoral activity and therefore represent potential targets for immunotherapeutic approaches in HCC treatment. However, the anti-tumoral activity of NK cells in HCC associated with different etiologies, and the impact of the heterogeneous NK cell subset, e.
View Article and Find Full Text PDFMatrix-induced autologous chondrocyte implantation (MACI) in the knee: clinical outcomes and challenges.
Knee Surg Sports Traumatol Arthrosc
December 2015
Purpose: Matrix-induced autologous chondrocyte implantation (MACI) has demonstrated effectiveness in treating isolated cartilage defects of the knee but medium- and long-term evidence and information on the management of postoperative complications or partially successful cases are sparse. This study hypothesised that MACI is effective for up to 5 years and that patients with posttreatment problems may go on to obtain clinical benefit from other interventions.
Methods: A follow-on, prospective case series of patients recruited into a previous controlled, randomised, prospective study or newly enroled.